Wave Life Sciences (0VS) Price & Analysis

3 Followers

0VS Stock Chart & Stats

€4.88

-€0.04(-0.81%)

At close: Jul 29 4:00 PM EDT

€4.88

-€0.04(-0.81%)

Day’s Range― - ―

52-Week Range€2.89 - €17.80

Previous CloseN/A

VolumeN/A

Average Volume (3M)138.00

Market Cap

€608.04M

Enterprise Value€738.28M

Total Cash (Recent Filing)€490.60M

Total Debt (Recent Filing)€43.59M

Price to Earnings (P/E)―

Beta2.05

Next Earnings

Nov 05, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.09

Shares Outstanding197,048,170

10 Day Avg. Volume2

30 Day Avg. Volume138

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)5.45

Price to Sales (P/S)67.10

P/FCF Ratio-15.29

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€18.13

Price Target Upside271.51% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-1.02

Revenue Forecast (FY)€45.42M

Bulls Say, Bears Say

Bulls Say

WVE-006 Regulatory PathwayFDA alignment on the WVE-006 registrational design reduces uncertainty around a potentially pivotal development path. The one-year biomarker analysis could support accelerated approval, creating a clearer route toward commercialization for a serious, genetically defined disease.

Strong Cash RunwayThe substantial cash balance and runway into Q3 2028 give Wave time to advance multiple clinical programs without immediate financing pressure. This supports sustained investment in development, preserves strategic flexibility, and lowers near-term liquidity risk.

Broad RNA Medicines PipelineProgress across obesity, alpha-1 antitrypsin deficiency, and PNPLA3 liver disease provides several potential value drivers rather than reliance on one asset. Early clinical and preclinical results, combined with advancing development stages, support a durable pipeline foundation.

Bears Say

Persistent Losses And Cash BurnWave remains far from profitability, with large operating and net losses translating into substantial cash outflow. Continued investment is necessary to advance the pipeline, so financial sustainability depends on the cash balance, collaboration receipts, milestones, or future capital.

Declining Collaboration RevenueThe sharp decline in collaboration revenue highlights the uneven nature of Wave’s current funding model and its reliance on partner-related receipts. Volatile revenue can make operating performance difficult to sustain while internal programs continue consuming significant resources.

Clinical And Regulatory Execution RiskWave’s future value depends on clinical readouts and regulatory decisions that remain subject to timing and outcome uncertainty. Partnership-dependent programs may also change direction or be delayed, making pipeline conversion into approvals and recurring revenue less predictable.

Wave Life Sciences News

Midday Fly By: Micron earnings beat, MSG Sports approves Rangers spinoff

The major averages were lower near noon to start the month as rising Treasury yields continue to weigh...

12d ago

Wave Life Sciences announces FDA feedback supports pathway for WVE-006

Wave Life Sciences (WVE) announced alignment with the U.S. Food and Drug Administration, FDA, on key aspects of...

12d ago

WVE

Wave Life Sciences initiated with a Buy at Ladenburg

Ladenburg analyst Rick Bienkowski initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $10 price...

12d ago

WVE

Wave Life announces GSK’s selection of siRNA program to transition to GSK

Wave Life Sciences (WVE) announced that as part of the companies’ research collaboration, GSK (GSK) has selected a...

13d ago

GSK

WVE

Wave Life Sciences resumed with a Neutral at JPMorgan

JPMorgan resumed coverage of Wave Life Sciences (WVE) with a Neutral rating and no price target Share upside...

20d ago

WVE

Wave Life Sciences initiates Phase 2a combination trial of WVE-007

Wave Life Sciences (WVE) announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA,...

20d ago

WVE

Wave Life Sciences: FDA-Aligned AATD Registrational Path, Obesity Combination Study, and GSK Milestones Underscore Buy Rating and $42 Price Target

Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Wave Life Sciences, with a price target...

6d ago

WVE

Alec Stranahan Maintains Buy Rating on Wave Life Sciences with Unchanged $17 Price Target Amid Multiple Clinical Catalysts

Analyst Alec Stranahan of Bank of America Securities maintained a Buy rating on Wave Life Sciences, retaining the...

2M ago

WVE

0VS FAQ

What was Wave Life Sciences’s price range in the past 12 months?

Wave Life Sciences lowest stock price was €2.89 and its highest was €17.80 in the past 12 months.

What is Wave Life Sciences’s market cap?

Wave Life Sciences’s market cap is €608.04M.

When is Wave Life Sciences’s upcoming earnings report date?

Wave Life Sciences’s upcoming earnings report date is Nov 05, 2026 which is in 23 days.

How were Wave Life Sciences’s earnings last quarter?

Wave Life Sciences released its earnings results on Jul 30, 2026. The company reported -€0.304 earnings per share for the quarter, missing the consensus estimate of -€0.269 by -€0.036.

Is Wave Life Sciences overvalued?

According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wave Life Sciences pay dividends?

Wave Life Sciences does not currently pay dividends.

What is Wave Life Sciences’s EPS estimate?

Wave Life Sciences’s EPS estimate is -0.3.

How many shares outstanding does Wave Life Sciences have?

Wave Life Sciences has 197,048,170 shares outstanding.

What happened to Wave Life Sciences’s price movement after its last earnings report?

Wave Life Sciences reported an EPS of -€0.304 in its last earnings report, missing expectations of -€0.269. Following the earnings report the stock price went down -2.459%.

Which hedge fund is a major shareholder of Wave Life Sciences?

Currently, no hedge funds are holding shares in DE:0VS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Wave Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-50.12%

Trailing 12-Months

Asset Growth

121.24%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Wave Life Sciences (0VS) Earnings & Revenues

Historic Earnings Reports

0VS Earnings Call

Q2 2026

0:00 / 0:00

0VS Stock 12 Month Forecast

Average Price Target

€18.13

▲(271.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","11":"€11","20":"€20","29":"€29","38":"€38"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37.60266888,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€37.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.129858210000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.9530164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,11,20,29,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,6.03097452923077,8.66194905846154,11.292923587692309,13.923898116923079,16.554872646153846,19.185847175384616,21.816821704615386,24.447796233846155,27.078770763076925,29.709745292307694,32.340719821538464,34.97169435076923,{"y":37.60266888,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,4.533066016153846,5.666132032307692,6.799198048461538,7.932264064615385,9.06533008076923,10.198396096923076,11.331462113076924,12.46452812923077,13.597594145384615,14.730660161538461,15.863726177692309,16.996792193846154,{"y":18.129858210000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.8271551076923074,4.254310215384615,4.681465323076923,5.10862043076923,5.535775538461538,5.962930646153845,6.390085753846153,6.81724086153846,7.244395969230768,7.671551076923075,8.098706184615382,8.525861292307692,{"y":8.9530164,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.35,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.035,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >